ABT 10-K Analysis: Abbott's $23B Bet on Its Lowest-Return Division
Abbott Laboratories reported $44.3 billion in revenue and a 52nd consecutive dividend increase — the kind of headline that signals a diversified compounder. But the 10-K's segment footnotes reveal that Medical Devices generates 61% of segment operating income, the $23 billion Exact Sciences acquisition targets the lowest-return division, and 1,760 infant formula lawsuits carry zero reserves. Here's what the filing reveals about the real risk-reward behind a 33.6× P/E.